You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study
|
|---|---|
| Published in |
BMC Complementary Medicine and Therapies, August 2017
|
| DOI | 10.1186/s12906-017-1933-7 |
| Pubmed ID | |
| Authors |
Angèle Guilbot, Marie Bangratz, Samira Ait Abdellah, Christian Lucas |
| Abstract |
Feverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study. Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months. Supplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated. Results suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study. ClinicalTrials.gov: NCT02901756 , retrospectively registered on August 24, 2016. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| Canada | 1 | 11% |
| Brazil | 1 | 11% |
| Unknown | 4 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Practitioners (doctors, other healthcare professionals) | 3 | 33% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 137 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 137 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 28 | 20% |
| Student > Master | 14 | 10% |
| Other | 11 | 8% |
| Researcher | 10 | 7% |
| Student > Doctoral Student | 6 | 4% |
| Other | 20 | 15% |
| Unknown | 48 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 16% |
| Nursing and Health Professions | 18 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 9% |
| Agricultural and Biological Sciences | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 7 | 5% |
| Other | 17 | 12% |
| Unknown | 53 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2023.
All research outputs
#1,280,395
of 25,652,464 outputs
Outputs from BMC Complementary Medicine and Therapies
#200
of 3,982 outputs
Outputs of similar age
#25,137
of 324,291 outputs
Outputs of similar age from BMC Complementary Medicine and Therapies
#6
of 107 outputs
Altmetric has tracked 25,652,464 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,982 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,291 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.